Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 17/20 | 0.53 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386304 | 1.00 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11ALDH1A1 | |
| SCHEMBL14938792 | 0.98 | SLC5A2 (0.52) | SLC5A2SLC5A1ADRA2ASLC5A11ALDH1A1 | |
| SCHEMBL16608734 | 0.88 | PKM (0.46) | SLC5A2SLC5A1 | |
| SCHEMBL3680232 | 0.88 | SLC5A2 (0.52) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL10211827 | 0.88 | SLC5A2 (0.44) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL38651021 | 0.86 | L3MBTL1 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL27368089 | 0.86 | L3MBTL1 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL15397883 | 0.85 | HTR2A (0.42) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL3680551 | 0.85 | SLC5A2 (0.52) | SLC5A2SLC5A1ADRA2ASLC5A11ALDH1A1 | |
| SCHEMBL30263682 | 0.84 | SLC5A2 (0.50) | SLC5A2SLC5A1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118908926-A | Dapagliflozin Net synthesis method | 安徽海康药业股份有限公司 | 2024-11-08 | — | — | CN | claimed |
| CN-220603103-U | Vibration device for detecting 5-bromo-2-chloro-4' -ethoxy diphenylmethane | 福建未来药业有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-117658784-A | Preparation method of dapagliflozin intermediate | 山东诚汇双达药业有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-117624259-A | Preparation method of dapagliflozin intermediate | 珠海润都制药股份有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-117624100-A | Efficient production process of dapagliflozin | 宣城美诺华药业有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-117551153-A | Method for synthesizing dapagliflozin intermediate through continuous reaction | 哈药集团技术中心 | 2024-02-13 | — | — | CN | claimed |
| CN-220367033-U | Sample extraction device for detecting 5-bromo-2-chloro-4' -ethoxy diphenylmethane | 福建未来药业有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-113620986-B | Method for synthesizing medicine for treating diabetes by using D-gluconic acid-delta-lactone | 沧州那瑞化学科技有限公司 | 2024-01-02 | — | — | CN | claimed |
| CN-114394993-B | Preparation method of dapagliflozin intermediate | 苏州正济药业有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-114577944-B | Detection method for related substances in 5-bromo-2-chloro-4' -ethoxydiphenylmethane | 山东鲁抗医药股份有限公司 | 2023-08-15 | — | — | CN | claimed |
| US-20190144411-A1 | Process for the preparation of (1S)-1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl) methyl]phenyl]-D-glucitol and its solvate thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2019-05-16 | — | — | US | claimed |
| US-20170247356-A1 | PROCESSES FOR THE PREPARATION OF EMPAGLIFLOZIN | CADILA HEALTHCARE LIMITED | 2017-08-31 | — | — | US | claimed |
| EP-2933250-B1 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF | TIANJIN INST OF PHARMACEUTICAL RES (CN) | 2017-08-09 | — | — | EP | claimed |
| US-20170029398-A1 | PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-{4-CHLORO-3-4[(4-ETHOXYPHENYL)METHYL]PHENYL]-GLUCITOL AND ITS SOLVATE THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-02-02 | — | — | US | claimed |
| EP-3114115-A2 | PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-[4-CHLORO-3-[(4-ETHOXYPHENYL)METHYL]PHENYL]-D-GLUCITOL AND ITS SOLVATE THEREOF | MSN Laboratories Private Limited (IN) | 2017-01-11 | — | — | EP | claimed |
| US-9505734-B2 | Phenyl C-glucoside derivative containing deoxyglucose structure, preparation method and use thereof | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2016-11-29 | — | — | US | claimed |
| WO-2016147197-A1 | A NOVEL PROCESS FOR PREPARING (2S,3R,4R,5S,6R)-2-[4-CHLORO-3-(4-ETHOXYBENZYL)PHENY 1] -6-(HY DROXY METHYL)TETRAHYDRO-2H-PY RAN-3,4,5-TRIOL AND ITS AMORPHOUS FORM | HARMAN FINOCHEM LIMITED (IN) | 2016-09-22 | — | — | WO | claimed |
| US-20160046595-A1 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2016-02-18 | — | — | US | claimed |
| EP-2933250-A1 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF | Tianjin Institute Of Pharmaceutical Research (CN) | 2015-10-21 | — | — | EP | claimed |
| WO-2015132803-A2 | PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-[4-CHLORO-3-[(4-ETHOXYPHENYL)METHYL]PHENYL]-D-GLUCITOL AND ITS SOLVATE THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-09-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029398-A1 | PROCESS FOR THE PREPARATION OF (1S)-1,5-ANHYDRO-1-C-{4-CHLORO-3-4[(4-ETHOXYPHENYL)METHYL]PHENYL]-GLUCITOL AND ITS SOLVATE THEREOF | ADH1C, ALG1, UGGT1 | SLC5A2 94/4885SLC5A1 8/4885ADRA2A 2580/4885 |
| US-20170247356-A1 | PROCESSES FOR THE PREPARATION OF EMPAGLIFLOZIN | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 2784/4885 |
| US-20190144411-A1 | Process for the preparation of (1S)-1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl) methyl]phenyl]-D-glucitol and its solvate thereof | ADH1C, ALG1, UGGT1 | SLC5A2 93/4885SLC5A1 9/4885ADRA2A 2638/4885 |
| US-20160046595-A1 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF | GCG, SLC5A1, DPP7 | SLC5A2 6/4885SLC5A1 2/4885ADRA2A 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.